AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05789004 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth Bleaching with Whiteness HP Automixx 35%
Description: * Clinical examination and taking the initial shade of the tooth with Vita Easyshade®;~* Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~* Prophylaxis with a Robson brush and prophylactic paste;~* Application of lip balm on the patient's lips;~* Placement of the labial retractor;~* Application of the gingival barrier;~* Application of Whiteness HP Automixx 35% whitening gel;~* In the session, a single application of the gel will be carried out and where it will remain on the surface of the tooth for 15 min;~* The gel must be removed from the teeth with a sucker and the teeth cleaned with gauze;~* Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~* The second bleaching session will be carried out 7 days after the first one and, if necessary, a third session can be carried out 7 days after the second one.
Study NCT05789004 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth Bleaching with Whiteness HP Automixx 6%
Description: * Clinical examination and taking the initial shade of the tooth with Vita Easyshade®;~* Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~* Prophylaxis with a Robson brush and prophylactic paste;~* Application of lip balm on the patient's lips;~* Placement of the labial retractor;~* Application of the gingival barrier;~* Application of Whiteness HP Automixx 6% whitening gel;~* In the session, a single application of the gel will be carried out and where it will remain on the surface of the tooth for 15 min;~* The gel must be removed from the teeth with a sucker and the teeth cleaned with gauze;~* Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~* The second bleaching session will be carried out 7 days after the first one and, if necessary, a third session can be carried out 7 days after the second one.
Study NCT06449534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Therapy
Description: Participants in both groups were included in a structured exercise program consisting of exercises recommended in the literature. This exercise program includes joint range of motion exercises, stretching exercises and strengthening exercises and was carried out under the supervision of a physiotherapist for 6 weeks. Joint range of motion and strengthening exercises are recommended as 3 sets of 10 repetitions, and stretching exercises are recommended as 5 repetitions for 20 seconds. Exercises appropriate to the patients' clinical conditions and progression were selected by the physiotherapist and included in the program.
Study NCT06449534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cold Application
Description: Following each exercise treatment, cold-pack will be applied for 15 minutes. During col-pack application, patients in the Group 1 group will listen to classical music selected by us, while patients in the Group 2 will rest quietly. There are a total of 40 songs by Bach, Mozart, Beethoven and Andre Rieu on our CD player, and patients have the right to choose and listen to the song they want.
Study NCT04963270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satralizumab
Description: Satralizumab will be administered as a subcutaneous injection
Study NCT04963270 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Satralizumab placebo will be administered as a subcutaneous injection
Study NCT04934098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable Compression Wrap
Description: The material will be delivered, adapted, and oriented for the daily use of the adjustable compression wrap (Ready Wrap®). The wrap allows for easy use because it is the pre-molded system in inelastic material with self-adjusting compressible components according to the size and shape of the upper limb. Due to its compression properties, it can be used as a therapy to control lymphedema. The material composition is: 61% Nylon, 33% Polyurethane, 6% Elastane (Spandex)). The institutional protocol for the control of the lymphedema phase will be respected, in which the orthosis is used at home for the longest period possible, with the only removal for bathing and sleeping; in addition, skincare and therapeutic exercises for the upper limbs should be performed daily.
Study NCT04934098 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression Bandage
Description: Evaluation, skincare, compression bandaging, and guidance on therapeutic exercises for upper limbs. The material used for binding is tubular mesh, foam, elastic compression bandage. Therapy will be followed according to the institutional protocol for the lymphedema reduction phase, in which it will be reassessed twice a week for 30 days.
Study NCT06425536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home use
Description: Home use twice a day
Study NCT05160610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multilevel intervention
Description: Multilevel intervention based on AACTT theory
Study NCT05695664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Description: Intravenous injection of ibuprofen 800 mg
Study NCT05695664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Injection
Description: Intravenous injection of Ketorolac 30 mg
Study NCT05909527 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD7 CAR-T
Description: A single infusion of autologous CD7 CAR-T cells administered intravenously
Study NCT05152264 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Treatment with transcutaneous electrical nerve stimulation (TENS) during 16 weeks.
Study NCT05152264 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional analgesic treatment
Description: Conventional analgesic treatment. Conventional analgesic treatment may include no pharmacological treatment if the patient does not use any analgesics.
Study NCT05784961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS will be delivered using this electrode montage: anode on the left dosolateral prefrontal cortex (L DLPFC) using F3 EEG landmark and cathode on the left temporoparietal junction (L TPJ) on the middle point between T3 and P3 EEG landmark.~The stimulation will be delivered at an intensity of 2 milliamps, for 20 minutes, five times a day, with 20 min inter sessions (it will be carried out on 5 consecutive days from Monday to Friday). Each processing day corresponds to a visit of V2, V3, V4, V5 and V6.
Study NCT05784961 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tDCS
Description: tDCS will be delivered using this electrode montage: anode on the left dosolateral prefrontal cortex (L DLPFC) using F3 EEG landmark and cathode on the left temporoparietal junction (L TPJ) on the middle point between T3 and P3 EEG landmark.~The stimulation will be delivered at an intensity of 2 milliamps, for 20 minutes, five times a day, with 20 min inter sessions (it will be carried out on 5 consecutive days from Monday to Friday). Each processing day corresponds to a visit of V2, V3, V4, V5 and V6.
Study NCT06411561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SLEEP + COG
Description: Combination of SLEEP and COG interventions
Study NCT06411561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COG
Description: Daily 30-minute session of computerized cognitive training
Study NCT06411561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SLEEP
Description: Nighttime use of both ear plugs and eye masks
Study NCT06411561 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AC
Description: Educational modules on cognitive and sleep health
Study NCT06425536 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home use
Description: Home use twice a day
Study NCT06556602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MPACT
Description: Four components are part of this intervention: 1) accredited training about patient centered, trauma-informed care and the standard of care under the current federal regulation (42CFRpart8), 2) education about trauma and trauma symptoms including vicarious (work related) trauma and navigation to symptoms screening and resources including treatment, 3) reflective supervision for counseling, case management and peer staff, and 4) clinic self assessment for trauma-informed and patient centered care
Study NCT05861973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive SMARTer intervention (SMARTer)
Description: Participants will receive calorie, fat, and physical activity goals, a Smartphone application for self-monitoring their diet, activity and weight, online educational readings, and brief bi-weekly remote health sessions with a Health Promotionist. They will also be loaned a Fitbit tracking device and a wireless bluetooth scale for 6 months.
Study NCT05861973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program Participants (DPP)
Description: In accordance with the Center for Disease Control curriculum, participants will receive a participant log for tracking physical activity, food intake, and weight, a paper participant guide with worksheets, logs, and psycho-educational materials, and 16 hour long remote sessions with a Health Promotionist.
Study NCT05643287 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal treatment
Description: Non-surgical periodontal treatment
Study NCT06610032 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mesotherapy
Description: A total of 3 sessions of mesotherapy will be applied to the shoulder area of the patients, 7 days apart in group 1.
Study NCT06610032 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular steroid injection
Description: Single session intra-articular 20 mg triamcinolone hexacetonide injection will be applied for patients in group 2.
Study NCT06664957 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C (Ascorbic Acid)
Description: Participants in this arm will receive 400 mg of Vitamin C, administered as two 100 mg tablets in the morning and two 100 mg tablets in the evening, for a total of 12 months. The intervention aims to support antioxidant defense and improve clinical outcomes in COPD patients.
Study NCT06664957 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in this group will receive a placebo, identical in appearance to the active nutrient supplement (Vitamin C) tablets, with no active ingredients. The placebo will be administered as two tablets in the morning and two tablets in the evening (four tablets per day) for a duration of 12 months, serving as a control to compare the effects of the active intervention.
Study NCT06615141 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculus Quest 3
Description: Oculus quest 3 is a standalone virtual reality headset developed by Meta. It offers precise motion tracking and offers an innovative intervention for stroke rehabilitation, enhancing upper limb motor function throug task - specific exercises.
Study NCT06615141 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neofect Smartboard and Tyromotion Myro
Description: Neofect Smart Board provides non-immersive VR rehabilitation through gamified, task specific exercises to improve upper limb mobility in an interactive way.~Tyromotion Myro uses non-immersive VR therapy combining sensor-based feedback and interactive games to enhance fine motor skills.
Study NCT05748600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole Dihydrochloride
Description: administration of dexpramipexole tablet
Study NCT05748600 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administration of placebo tablet
Study NCT05206838 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical reconstruction of gluteus medius with Achilles tendon allograft
Description: Achilles tendon allograft i fixed between the gluteus medius muscle and the greater trochanter
Study NCT05493163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thrombolytic
Description: Local, catheter-directed thrombolysis with a total dose of 10mg per affected lung administered over 9 hours.
Study NCT05493163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard anticoagulation
Description: Standard anticoagulation therapy of acute pulmonary embolism.
Study NCT05705869 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Description: NT-proBNP will be measured in all participants in the Investigational arm. If the level of the NT-proBNP is elevated (≥125pg/mL) participants will undergo a full cart-based transthoracic echocardiogram along with a clinical examination for signs of HF and a HF symptom assessment. Participants with HF identified will be referred to their local HF clinic for ongoing management.
Study NCT06139133 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation
Description: Placebo
Study NCT06139133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Description: Vitamin D3 supplementation (2 00,000 IU/Week)
Study NCT06558968 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aesthetic functional space maintainers
Description: evaluate the use of Polyetheretherketone 'PEEK' and monolithic zirconia 'Bruxzir' as esthetic functional band and loop space maintainers.
Study NCT05661591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554 Tablets
Description: SHR2554 Tablets+ Fluconazole Capsules
Study NCT05661591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole Capsules
Description: SHR2554 Tablets+ Fluconazole Capsules
Study NCT06685146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucagon Infusion
Description: A 240 minutes infusion of glucagon (10 ng/kg/min)
Study NCT06685146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose clamp
Description: A 240 minutes infusion of 20 % w/v glucose. The infusion rate of glucose will be adjusted continuously to match the levels of glucose measured on the glucagon study day.
Study NCT05544123 — intervention group
Intervention type: OTHER
Intervention: pathological stage
Description: breast cancer molecular subtyping and pathological TNM stage
Study NCT04824066 — intervention group
Intervention type: DEVICE
Intervention: Device: Wearable Device
Description: A Wearable Device will be placed on the wrist of the patient \~30 days prior to the patient's scheduled surgery, removed during the operation, and replaced for \~180 days post-operatively. The device will record activity in terms of steps, sleep quality, heart rate, etc.
Study NCT06686797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-08049820
Description: Oral solution/suspension
Study NCT06686797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution/suspension
Study NCT06063031 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active
Description: Active nutritional supplement plus telerehabilitation
Study NCT06063031 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nutritional supplement plus telerehabilitation
Study NCT06559969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous administered opioid
Description: Hydromorphone will be received intravenously using a patient controlled administration pump, as well as patient will have a continuous bupivacaine epidural infusion
Study NCT06559969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural administered opioid
Description: Hydromorphone will be added to the bupivacaine in the epidural and will have a continuous infusion along with the ability for the patient to receive epidural boluses of the medications by a patient controlled epidural administration pump
Study NCT05639647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATM-AVI
Description: A drug specifically designed to treat resistant gam-negative bacterial infections
Study NCT05639647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAT
Description: BAT will be selected by the investigator and administered iv as appropriate for the selected drug(s)
Study NCT05261139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nirmatrelvir
Description: PF-07321332
Study NCT05261139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: ritonavir
Study NCT05704036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen
Description: Transdermal estradiol 0.1 mg/day, applied once weekly
Study NCT05971394 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)
Description: Subjects in this arm will be treated with Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)
Study NCT05704036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone 200 mg daily for 10 days/month, if participant is not on progesterone-containing contraceptive
Study NCT06420076 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD5/CD7 CAR-T
Description: The intervention in this clinical trial involves a novel approach using CD5/CD7 Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~CD5/CD7 Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD5/CD7 CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD5/CD7 CAR-T cell infusion without unacceptable side effects and sufficient CAR-T cell availability may receive 2 or 3 additional doses.
Study NCT06696326 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: standard-of-care imaging 68Ga-MY6349 and 68Ga-PSMA-11
Description: Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceuticals 68Ga-MY6349 and 68Ga-PSMA-11, and undergoes PET/CT imaging within the specified time.
Study NCT06719635 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Presacral Neurectomy
Description: Laparoscopy will be performed under general anesthesia. Then, nerve plexuses will be identified and freed from their underlying tissue, which contains the left common iliac and middle sacral veins. This will be followed by cauterization and cutting of the nerve plexuses.
Study NCT06719635 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopically guided Superior Hypogastric Plexus Neurolysis
Description: The patients will receive fluoroscopically guided Superior Hypogastric Plexus Neurolysis using 3 mL of 75% ethanol and Radiofrequency of the Sacral nerve Roots 2-4.
Study NCT06712719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LP then HP
Description: Each cross-over phase will be 21 days and consist of a 7-day outpatient, controlled diet period, followed by a 7-day inpatient, controlled diet, balance, and kinetic study period, followed by a second 7-day outpatient, controlled diet period.~LP then HP
Study NCT06712719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HP then LP
Description: Each cross-over phase will be 21 days and consist of a 7-day outpatient, controlled diet period, followed by a 7-day inpatient, controlled diet, balance, and kinetic study period, followed by a second 7-day outpatient, controlled diet period.~HP then LP
Study NCT06729112 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: pan immune inflammation value
Description: Using the ratio of neutrophil, monocyte, and platelet counts to lymphocyte count, NLR, MLR, and PLR were calculated. The pan immune inflammation value (PIV) was calculated by multiplying the neutrophil count by the platelet count and the monocyte count, and then dividing the result by the lymphocyte count.
Study NCT06734728 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Profilm Cold Sores
Description: The treatment will consist of daily applications of the product as soon as the first symptoms of an outbreak appear, and until the outbreak subsides, as follows: application every 8 hours, with the possibility of shortening the interval to 6 hours if needed (a maximum of 3-4 applications).
Study NCT06737744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Games for Change (AG4C)
Description: This intervention was carried out in Turkiye within the Erasmus+ Key Action 3 project titled Active Games for Change (AG4C). The programme included a series of innovative, face-to-face active games with a non-formal approach that prioritised physical activity, specifically designed to support the development of social and emotional competencies identified for the first time in the field in a probation directorate serving young adult offenders.
Study NCT06737744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Games for Change Group Working
Description: The Active Games for Change intervention program was implemented in Izmir, Türkiye within the Erasmus+ Key Action 3 project titled Active Games for Change (AG4C). The AG4C intervention program included a series of innovative, face-to-face active games with a non-formal approach that prioritised support for developing social and emotional competencies of young adults with substance use problems, for the first time in the field.